Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients | Zendy

Jinman Shao | Zendy; Yan Liu | Zendy; Liming Liu | Zendy; Rongjuan Chen | Zendy; Li Zhao | Zendy; Yi Zhou | Zendy; Le Li | Zendy; Xiaodong Li | Zendy; Jin Li | Zendy; Dongping Xu | Zendy

Open Access

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients

Author(s) -

Jinman Shao,

Yan Liu,

Liming Liu,

Rongjuan Chen,

Li Zhao,

Yi Zhou,

Le Li,

Xiaodong Li,

Jin Li,

Dongping Xu

Publication year - 2021

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.12643

Subject(s) - entecavir , adefovir , hepatitis b virus , virology , drug resistance , medicine , multiple drug resistance , mutant , hepatitis b , mutation , hbsag , biology , lamivudine , virus , gene , microbiology and biotechnology , genetics

Adefovir plus entecavir (ADV+ETV) rescue therapy in ETV-resistant patients with chronic hepatitis B virus (HBV) infection is suboptimal in some patients. This study aims to elucidate the evolutionary characteristics of drug-resistant HBV mutants and their association with clinical responses in such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research